| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ITGb8 |
| Uniprot No | P26012 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-769aa |
| 氨基酸序列 | MCGSALAFFTAAFVCLQNDRRGPASFLWAAWVFSLVLGLGQGEDNRCASSNAASCARCLALGPECGWCVQEDFISGGSRSERCDIVSNLISKGCSVDSIEYPSVHVIIPTENEINTQVTPGEVSIQLRPGAEANFMLKVHPLKKYPVDLYYLVDVSASMHNNIEKLNSVGNDLSRKMAFFSRDFRLGFGSYVDKTVSPYISIHPERIHNQCSDYNLDCMPPHGYIHVLSLTENITEFEKAVHRQKISGNIDTPEGGFDAMLQAAVCESHIGWRKEAKRLLLVMTDQTSHLALDSKLAGIVVPNDGNCHLKNNVYVKSTTMEHPSLGQLSEKLIDNNINVIFAVQGKQFHWYKDLLPLLPGTIAGEIESKAANLNNLVVEAYQKLISEVKVQVENQVQGIYFNITAICPDGSRKPGMEGCRNVTSNDEVLFNVTVTMKKCDVTGGKNYAIIKPIGFNETAKIHIHRNCSCQCEDNRGPKGKCVDETFLDSKCFQCDENKCHFDEDQFSSESCKSHKDQPVCSGRGVCVCGKCSCHKIKLGKVYGKYCEKDDFSCPYHHGNLCAGHGECEAGRCQCFSGWEGDRCQCPSAAAQHCVNSKGQVCSGRGTCVCGRCECTDPRSIGRFCEHCPTCYTACKENWNCMQCLHPHNLSQAILDQCKTSCALMEQQHYVDQTSECFSSPSYLRIFFIIFIVTFLIGLLKVLIIRQVILQWNSNKIKSSSDYRVSASKKDKLILQSVCTRAVTYRREKPEEIKMDISKLNAHETFRCNF |
| 预测分子量 | 85,6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于ITGb8重组蛋白的参考文献示例(内容基于假设性研究，建议核实真实文献)：
---
1. **文献名称**: *"Integrin β8-mediated TGF-β activation is critical for immune regulation"*
**作者**: Travis MA, et al.
**摘要**: 研究重组ITGb8蛋白在调节TGF-β信号通路中的作用，发现其通过与αv整合素结合激活TGF-β，进而抑制T细胞免疫反应，可能为自身免疫疾病治疗提供靶点。
2. **文献名称**: *"Structural insights into integrin β8 activation mechanisms"*
**作者**: Cambier L, et al.
**摘要**: 通过重组表达ITGb8蛋白解析其晶体结构，揭示其与配体结合的构象变化，阐明其在细胞黏附和信号转导中的分子机制。
3. **文献名称**: *"Recombinant integrin β8 regulates angiogenesis in tumor microenvironment"*
**作者**: Vanderheyden K, et al.
**摘要**: 利用重组ITGb8蛋白研究其在肿瘤血管生成中的作用，发现其通过调控内皮细胞迁移和TGF-β通路抑制肿瘤血管形成。
---
如需准确文献，建议在PubMed或Google Scholar检索关键词“integrin beta8 recombinant”或“ITGb8 recombinant protein”。
**Background of Recombinant ITGb8 Protein**
Integrin beta-8 (ITGb8) is a subunit of the integrin family, a group of heterodimeric transmembrane receptors composed of α and β subunits that mediate cell-cell and cell-extracellular matrix (ECM) interactions. ITGb8 specifically pairs with the αv subunit to form the integrin αvβ8 heterodimer, which plays critical roles in cell adhesion, signaling, and tissue homeostasis. Unlike many integrins, αvβ8 does not bind classical ECM ligands like fibronectin or collagen. Instead, it interacts with latency-associated peptide (LAP) complexes to activate transforming growth factor-beta (TGF-β), a key regulator of immune tolerance, angiogenesis, and tissue remodeling.
The ITGb8 subunit is highly expressed in epithelial, endothelial, and neural cells, where its TGF-β-activating function is essential for vascular development, neurogenesis, and immune modulation. Dysregulation of ITGb8 has been linked to pathologies such as cancer metastasis, fibrosis, and autoimmune disorders. For example, in cancer, αvβ8-mediated TGF-β activation can promote immunosuppression and tumor progression, while in the nervous system, ITGb8 deficiency disrupts cerebral vascularization and neuronal migration.
Recombinant ITGb8 protein is engineered in vitro using expression systems like mammalian or insect cells to ensure proper post-translational modifications. It is purified via affinity tags (e.g., His-tag) and validated for functional activity, often through binding assays with αv or TGF-β LAP. This recombinant tool enables researchers to study ITGb8’s structural interactions, signaling mechanisms, and therapeutic potential. Applications include screening for inhibitors targeting αvβ8-TGF-β pathways in cancer or fibrosis, as well as exploring its role in neurodevelopmental disorders. By providing a controlled source of functional ITGb8. recombinant protein technology advances both basic research and drug development in biomedicine.
×
